Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.
Punekar S, Weber J. Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out. Clinical Cancer Research 2022, 28: 5007-5009. PMID: 36161479, DOI: 10.1158/1078-0432.ccr-22-2427.Peer-Reviewed Original ResearchImmunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapy